Daan P. Hurkmans

Impact of a diagnostic strategy for appendicitis in children with acute abdominal pain in primary care: study protocol for a hybrid type 1 cluster randomised controlled trial

Esmee M. Hogervorst, Roderick P Venekamp, Grietje E. Knol‐de Vries, Tamara N Platteel et autres

BACKGROUND: Children with acute abdominal pain pose a diagnostic challenge for general practitioners (GPs), as it can be difficult to distinguish appendicitis from self-limiting conditions due to overlapping symptoms. To support GPs, a diagnostic strategy for appendicitis was developed that integrates an …

nl, vn (code pays fourni par la source)

Additional file 1 of Impact of a diagnostic strategy for appendicitis in children with acute abdominal pain in primary care: study protocol for a hybrid type 1 cluster randomised controlled trial

Esmee M. Hogervorst, Roderick P Venekamp, Grietje E. Knol‐de Vries, Tamara N Platteel et autres

Supplementary Material 1.

nl (code pays fourni par la source)

Additional file 1 of Impact of a diagnostic strategy for appendicitis in children with acute abdominal pain in primary care: study protocol for a hybrid type 1 cluster randomised controlled trial

Esmee M. Hogervorst, Roderick P Venekamp, Grietje E. Knol‐de Vries, Tamara N Platteel et autres

Supplementary Material 1.

nl (code pays fourni par la source)

Long-term survivors of melanoma after anti–PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood

Karlijn de Joode, Hayri E. Balcıoğlu, Mandy van Brakel, María T. Lopez-Cascales et autres

Anti-PD-1 monotherapy has shown a significant survival benefit for patients with advanced-stage melanoma. In this study, we explored whether long-term clinical benefit is determined by abundance or changes in such abundances of CD4 and CD8 T-cell subsets in blood. Peripheral blood mononuclear …

us, nl (code pays fourni par la source)

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study

Karlijn de Joode, Harry J.M. Groen, Michel van den Heuvel, Jeroen S. Kloover et autres

BACKGROUND: The programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) is used as a biomarker to predict benefit from immune checkpoint blockade (ICB) in patients with non-small cell lung cancer (NSCLC). However, additional biomarkers are needed. The potential of kinase activity profiling …

nl (code pays fourni par la source)

Re: Policy Versus Practice: Facilitators and Barriers of Chronic Care Integration in Dutch General Practice – a Survey Study

Daan P. Hurkmans, Eva de Bie

The aim of this Letter to Editor is to point out the impact of some of the article's conclusions, while in our opinion these conclusions might not be accurate based on the detailed results. The authors report that 56% of health care …

nl (code pays fourni par la source)

Blood based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer: The IOpener study.

Karlijn de Joode, Harry J.M. Groen, Michel M. van den Heuvel, Jeroen S. Kloover et autres

e20576 Background: Treatment with immune checkpoint inhibitors (ICI) has become part of the standard of care for patients with advanced stage non-small cell lung cancer (NSCLC). Unfortunately, its success is limited to a subset of treated patients, while ICI treatment is associated …

nl (code pays fourni par la source)

Vitiligo

Daan P. Hurkmans

Vitiligo is een goedaardige, verworven, chronische pigmentstoornis door verlies van functionele melanocyten, die meestal geleidelijk uitbreidend is. Een belangrijk deel van de klachten bij vitiligo is psychosociaal van aard. Er zijn verschillende …

Data from A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors

Mirte Muller, Karlijn Hummelink, Daan P. Hurkmans, Anna-Larissa N. Niemeijer et autres

AbstractPurpose: Pretreatment selection of patients with non–small cell lung cancer (NSCLC) who would derive clinical benefit from treatment with immune checkpoint inhibitors (CPIs) would fulfill an unmet clinical need by reducing unnecessary toxicities from treatment and result in substantial health care savings. …

Supplementary Data from A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors

Mirte Muller, Karlijn Hummelink, Daan P. Hurkmans, Anna-Larissa N. Niemeijer et autres

Supplementary Data from A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors

Supplementary Data from A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors

Mirte Muller, Karlijn Hummelink, Daan P. Hurkmans, Anna-Larissa N. Niemeijer et autres

Supplementary Data from A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors

Supplementary Data from A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors

Mirte Muller, Karlijn Hummelink, Daan P. Hurkmans, Anna-Larissa N. Niemeijer et autres

Supplementary Data from A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors